Tranexamic Acid Use in Post-Stroke Patients with Hematuria

Risk Assessment for TXA in Post-Stroke Patients

• Tranexamic acid is contraindicated in patients with active thromboembolic disease or history of thrombosis, making post-stroke patients a high-risk population 1
• The risk of precipitated thrombosis with tranexamic acid has been a major theoretical concern, particularly relevant in patients with recent cerebrovascular events 2

Special Considerations for Hematuria Management

• TXA should be used with caution in patients with massive hematuria due to risk of ureteric obstruction 1

Dosing Considerations

• If TXA must be used in a post-stroke patient with hematuria after careful risk-benefit assessment, standard dosing is 1g loading dose over 10 minutes, followed by 1g infusion over 8 hours 3
• Dose reduction is mandatory in patients with renal dysfunction as TXA is primarily renally excreted 1

Monitoring and Precautions

• Consider discontinuing TXA as soon as bleeding is controlled 1
• If surgery is planned, discontinue TXA 5 days before procedures with high bleeding risk 1
• Regular assessment of renal function is essential as impaired clearance increases risk of neurotoxicity and ocular toxicity 1